PH26554A - Inhibitory agent of hepatic fibrosis - Google Patents
Inhibitory agent of hepatic fibrosis Download PDFInfo
- Publication number
- PH26554A PH26554A PH38005A PH38005A PH26554A PH 26554 A PH26554 A PH 26554A PH 38005 A PH38005 A PH 38005A PH 38005 A PH38005 A PH 38005A PH 26554 A PH26554 A PH 26554A
- Authority
- PH
- Philippines
- Prior art keywords
- fibrosis
- pantethine
- hepatic
- hepatic fibrosis
- inhibitory agent
- Prior art date
Links
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims description 9
- 230000002401 inhibitory effect Effects 0.000 title claims description 9
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 11
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 11
- 229960000903 pantethine Drugs 0.000 claims description 11
- 235000008975 pantethine Nutrition 0.000 claims description 11
- 239000011581 pantethine Substances 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 5
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229940107161 cholesterol Drugs 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 101150039167 Bex3 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP106788 | 1988-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26554A true PH26554A (en) | 1992-08-19 |
Family
ID=11491185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH38005A PH26554A (en) | 1988-01-06 | 1989-01-05 | Inhibitory agent of hepatic fibrosis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4937266A (ko) |
| EP (1) | EP0323855B1 (ko) |
| KR (1) | KR970005324B1 (ko) |
| AU (1) | AU614569B2 (ko) |
| CA (1) | CA1318254C (ko) |
| DE (1) | DE68914468T2 (ko) |
| ES (1) | ES2054881T3 (ko) |
| PH (1) | PH26554A (ko) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02232670A (ja) * | 1989-03-06 | 1990-09-14 | Minolta Camera Co Ltd | 複写機 |
| US5789426A (en) * | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| US5965621A (en) * | 1995-08-17 | 1999-10-12 | Allergan | Methods and compositions for reducing or maintaining body weight in a mammal |
| WO2002098405A1 (fr) * | 2001-06-05 | 2002-12-12 | Ajinomoto Co., Inc. | Inhibiteurs de fibrose du foie |
| DK2712617T3 (en) | 2004-03-12 | 2017-02-13 | Intercept Pharmaceuticals Inc | Treatment of fibrosis with Fxr ligands. |
| LT2953948T (lt) | 2013-02-07 | 2018-01-10 | Scifluor Life Sciences, Inc | Fluorinti integrino antagonistai |
| RU2017132433A (ru) | 2015-02-19 | 2019-03-19 | Сайфлуор Лайф Сайенсиз, Инк. | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение |
| BR112017023432A2 (pt) | 2015-04-30 | 2018-07-24 | Scifluor Life Sciences Inc | Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo |
| WO2017189828A1 (en) | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019891B2 (ja) * | 1978-12-01 | 1985-05-18 | 第一製薬株式会社 | 薬物性脂肪肝用剤 |
| JPS55102567A (en) * | 1979-01-30 | 1980-08-05 | Dai Ichi Seiyaku Co Ltd | Nicotinoylpantethine derivative |
| JPS5835118A (ja) * | 1981-08-28 | 1983-03-01 | Dai Ichi Seiyaku Co Ltd | 肝炎治療剤 |
| GB2110536B (en) * | 1981-12-04 | 1986-10-29 | Sogo Pharm | Pharmaceutical compositions containing pantetheine-s-sulphonic acid |
-
1988
- 1988-12-29 CA CA000587236A patent/CA1318254C/en not_active Expired - Fee Related
-
1989
- 1989-01-03 US US07/292,793 patent/US4937266A/en not_active Expired - Fee Related
- 1989-01-04 AU AU27723/89A patent/AU614569B2/en not_active Ceased
- 1989-01-05 KR KR1019890000030A patent/KR970005324B1/ko not_active IP Right Cessation
- 1989-01-05 PH PH38005A patent/PH26554A/en unknown
- 1989-01-05 ES ES89100180T patent/ES2054881T3/es not_active Expired - Lifetime
- 1989-01-05 DE DE68914468T patent/DE68914468T2/de not_active Expired - Fee Related
- 1989-01-05 EP EP89100180A patent/EP0323855B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE68914468T2 (de) | 1994-07-28 |
| AU2772389A (en) | 1989-07-13 |
| EP0323855A3 (en) | 1990-12-05 |
| EP0323855A2 (en) | 1989-07-12 |
| ES2054881T3 (es) | 1994-08-16 |
| EP0323855B1 (en) | 1994-04-13 |
| AU614569B2 (en) | 1991-09-05 |
| US4937266A (en) | 1990-06-26 |
| KR970005324B1 (ko) | 1997-04-15 |
| DE68914468D1 (de) | 1994-05-19 |
| CA1318254C (en) | 1993-05-25 |
| KR890011588A (ko) | 1989-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Janoff et al. | Pathogenesis of experimental shock: IV. Studies on lysosomes in normal and tolerant animals subjected to lethal trauma and endotoxemia | |
| Middeldorp et al. | Effects on coagulation of levonorgestrel-and desogestrel-containing low dose oral contraceptives: a cross-over study | |
| PH26554A (en) | Inhibitory agent of hepatic fibrosis | |
| Valentine et al. | The relationship of leukocyte alkaline phosphatase to “stress,” to ACTH, and to adrenal 17-OH-corticosteroids | |
| Edwards et al. | Nitric oxide‐related vasodilator responses to parasympathetic stimulation of the submandibular gland in the cat. | |
| DE69530308D1 (de) | Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung | |
| Loeb et al. | Suppression of DNA synthesis in hepatoma cells exposed to glucocorticoid hormone in vitro | |
| Lazarow et al. | Protection against diabetes with nicotinamide | |
| DE2923009A1 (de) | Mittel zur prophylaxe und behandlung der fibrose | |
| ATE254847T1 (de) | Verfahren zur identifikation von verbindungen, welche die bindenden wechselwirkungen zwischen den vpr und rip-1 proteinen von hiv-1 aufheben können | |
| KIMBERLY | Pulse methylprednisolone in SLE | |
| Murphy | Response of adaptive rat liver enzymes to acute poisoning by organophosphate insecticides | |
| Neubert et al. | Induction of skeletal malformations in organ cultures of mammalian embryonic tissues | |
| Lee et al. | Age-related changes in esterase activity in rabbit eyes | |
| ROBERTSON | Serum cholinesterase deficiency I: disease and inheritance | |
| Zawalich et al. | Influence of staurosporine on glucose-mediated and glucose-conditioned insulin secretion | |
| Wanders et al. | First prenatal diagnosis of acyl‐CoA oxidase deficiency | |
| Dawson | Rate constants of carbamylation and decarbamylation of acetylcholinesterase for physostigmine and carbaryl in the presence of an oxime | |
| Kashfi et al. | Malonyl-CoA inhibits proteolysis of carnitine palmitoyltransferase | |
| Grodins et al. | Observations on the toxicities and choleretic activities of certain bile salts | |
| JP2690768B2 (ja) | 肝線維化抑制剤 | |
| Hartung et al. | Cholinesterase inhibition in the acute toxicity of alkyl-substituted 2-aminoethanols | |
| Levin et al. | Metabolism of phospholipides associated with cell division | |
| Verjee et al. | Effect of glucocorticoids on liver and blood cholinesterases | |
| Kambam et al. | Cimetidine does not affect plasma cholinesterase activity |